ATAI Life Sciences(ATAI) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Reported Earlier: 'Texas Lawmakers Take Up Bills To Expedite Access To Psychedelic Therapy' - Marijuana Moment
BenzingaApr 22 11:11 ET
Atai Life Sciences Started at Positive by Berenberg
Dow JonesApr 4 01:23 ET
$ATAI Stock Is up 14% Today. Here's What We See in Our Data.
Quiver QuantitativeApr 2 11:31 ET
World's First AI Stem Cell-engineered Cognitive AI Platform Launched by Irish-based Partsol
PR NewswireMar 31 15:15 ET
Atai Life Sciences CEO Discusses Major Data Readouts Expected Through 2025 - ICYMI | NASDAQ:ATAI, ETR:9VC
Proactive InvestorsMar 29 13:28 ET
Insider Purchase: 10% Owner at $ATAI Buys 1,800,000 Shares
Quiver QuantitativeMar 24 17:16 ET

Comments

Jaguar8

Mar 25 10:53

🔵Watchlist, MARCH 25,2025, Tuesday. NFA -DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...

32

8

1

Trytosaveabit

Mar 25 05:34

Insider buy!

$ATAI Life Sciences (ATAI.US)$

2

Teddy123

Mar 11 19:22

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

$ATAI Life Sciences (ATAI.US)$
Major Depression Breakthrough: atai Sciences Launches Novel DMT Trial for Treatment-Resistant Patients

74425369

Mar 10 19:40

INSIDER BUY ALERT: JANX

What happened: In recent weeks, $Janux Therapeutics (JANX.US)$ has seen significant insider buying, notably from RA Capital Management, which acquired shares worth approximately $25.3M.
Big picture: Janux's stock has been volatile, trading near its 52-week low. Investor sentiment remains cautious amidst broader biotech sector challenges.
Key Developments:
📊 Positive Clinical Data: JANX007 showed impressive results in Phase 1 trials for metastatic castration-resistant prost...